Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Primary Care
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
Related Questions
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How would you manage a patient with metastatic hormone sensitive prostate cancer who received docetaxel but has toxicity while on darolutamide (+ leuprolide)??
What are your top takeaways in GU Cancers from ESMO 2024?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
